Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.56 |
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439709 | 1.00 | ATR (0.56) | ATRMETAP1SMN1; SMN2HTTKMT2A | |
| SCHEMBL27879703 | 0.85 | ATR (0.47) | ATRMETAP1SMN1; SMN2HTTKMT2A | |
| SCHEMBL3243855 | 0.83 | METAP1 (0.56) | ATRMETAP1RAB9APOLBLMNA | |
| SCHEMBL15266282 | 0.83 | METAP1 (0.56) | ATRMETAP1RAB9APOLBLMNA | |
| SCHEMBL6868944 | 0.83 | METAP1 (0.56) | ATRMETAP1KMT2ARAB9APOLB | |
| SCHEMBL2392457 | 0.83 | METAP1 (0.56) | ATRMETAP1KMT2ARAB9APOLB | |
| SCHEMBL30668778 | 0.83 | METAP1 (0.56) | ATRMETAP1RAB9APOLBLMNA | |
| SCHEMBL30681980 | 0.82 | METAP1 (0.53) | ATRMETAP1KMT2ARAB9APOLB | |
| SCHEMBL2083740 | 0.82 | METAP1 (0.53) | ATRMETAP1KMT2ARAB9APOLB | |
| SCHEMBL1580424 | 0.82 | METAP1 (0.55) | ATRMETAP1HTTKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4467199-A2 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118908957-A | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-11-08 | — | — | CN | disclosed |
| EP-3976597-B1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| CN-114222737-B | Small molecule inhibitors of NF- κB induced kinase | 詹森药业有限公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-20 | — | — | US | disclosed |
| US-11840531-B2 | CDK8/19 inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| EP-2585462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2012-01-05 | — | — | US | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110288090-A1 | Inhibitors of AKT Activity | MERCK SHARP & DOHME CORP. | 2011-11-24 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-2142516-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | Sanofi-Aventis (FR) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840531-B2 | CDK8/19 inhibitors | CDK8, CDK9, CDK18 | ATR 414/4885METAP1 4044/4885SMN1; SMN2 1571/4885 |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | ATR 3765/4885METAP1 1923/4885SMN1; SMN2 2125/4885 |
| US-20120004240-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CD, PIK3CA, PIK3R5 | ATR 863/4885METAP1 2867/4885SMN1; SMN2 3442/4885 |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | ATR 3552/4885METAP1 1815/4885SMN1; SMN2 4540/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | ATR 3933/4885METAP1 20/4885SMN1; SMN2 4150/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | ATR 3093/4885METAP1 2671/4885SMN1; SMN2 4444/4885 |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | ATR 3586/4885METAP1 2653/4885SMN1; SMN2 4832/4885 |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, IKBKE | ATR 3526/4885METAP1 1637/4885SMN1; SMN2 4618/4885 |
| US-20110288090-A1 | Inhibitors of AKT Activity | PIK3CD, PIK3CA, PIK3CG | ATR 714/4885METAP1 2628/4885SMN1; SMN2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.